Tempus AI

Tempus AI's 15min chart shows MACD Death Cross, Bollinger Bands Narrowing

Tempus AI's IPS Biomarker Validation: A Catalyst for Precision Oncology Diagnostics?

Tempus AI Advances Hereditary Cancer Testing and Immunotherapy Prediction, Despite Share Price Decline

Bullish Thesis on Tempus AI: A High-Growth Healthcare Stock with Robust Competitive Advantage

Tempus AI Director Epstein David R sells 370 shares at $59.41 on 2026-02-02.

Catalyst<ul> <li>Most analysts rate TEM Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a weak state, and we need to pay attention to the risk of decline.</li> <li>Bearish signals are obviously dominant (6 bearish vs 0 bullish).</li> <li>Fund flow trends are negative for Small, Medium, and Extra-large orders, indicating outflows from larger investors.</li></ul>

Key Factors

Tempus AI's Immune Profile Score (IPS) outperforms conventional biomarkers in predicting immunotherapy outcomes, enhancing precision oncology diagnostics.Tempus AI completed 1,000,000 combined DNA and RNA tests, advancing hereditary cancer testing and immunotherapy prediction tools.Tempus AI generated $334.2 million in Q3 revenue, an 84.7% year-over-year increase, with gross profit rising 98.4% to $209.9 million.

TEM News